Stress ulcer prophylaxis in the intensive care unit
A multicentre 7-day inception cohort study

VERSION #12, DATE 01/11/2014

CONFIDENTIAL

This document is confidential and the property of Department of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet. No part of it may be transmitted, reproduced, published, or used without prior written authorization from the institution.

STATEMENT OF COMPLIANCE

This document is a protocol for a clinical research study. The study will be conducted in compliance with all stipulations of this protocol, the conditions of ethics committee approval, the NHMRC National Statement on Ethical Conduct in Human Research (2007) and the Note for Guidance on Good Clinical Practice (CPMP/ICH-135/95).
TABLE OF CONTENTS

1. INVESTIGATORS AND FACILITIES 4
   1.1 Study Locations 4
   1.2 Study Management 5
      1.2.1 Principal Investigators 5
      1.2.2 Statistician 6
      1.2.3 Steering and Management Committee 6
   1.3 Sponsor 7
   1.4 Funding and resources 7
2. INTRODUCTION AND BACKGROUND 7
   2.1 Background Information 7
   2.2 Research Question 7
   2.3 Rationale for Current Study 7
3. STUDY OBJECTIVES 8
   3.1 Primary Objective 8
4. STUDY DESIGN 8
   4.1 Type of Study 8
   4.2 Study Design Diagram 8
   4.3 Number of Subjects 8
   4.4 Expected Duration of Study 8
   4.5 Primary and Secondary Outcome Measures 8
5. SUBJECT ENROLLMENT 8
   5.1 Recruitment 8
   5.2 Eligibility Criteria 9
      5.2.1 Inclusion Criteria 9
      5.2.2 Exclusion Criteria 9
   5.3 Readmission to an ICU 9
   5.4 Patients transferred between hospitals 9
   5.5 Study Closure 9
6. CLINICAL AND LABORATORY ASSESSMENTS – METHODOLOGY 9
   6.1 Patient Evaluation 9
   6.2 Unit Evaluation 10
7. STATISTICAL METHODS 11
   7.1 Sample Size Estimation 11
   7.2 Population to be Analysed 11
   7.3 Statistical Analysis Plan 11
8. DATA HANDLING 11
   8.1 Records to be Kept / Data Collection 11
   8.2 Data Management / Quality control 11
   8.3 Study Record Retention 12
9. ADMINISTRATIVE ASPECTS 12
   9.1 Confidentiality 12
   9.2 Approvals 12
   9.3 Modifications of the Protocol 12
   9.4 Financial Disclosure and Obligations 12
10. USE OF DATA AND PUBLICATIONS POLICY 12
11. REFERENCES 14
12. APPENDIX 1 15
13. APPENDIX 2 16
PROTOCOL SYNOPSIS

Title
Stress ulcer prophylaxis in the intensive care unit. A multicentre 7-day inception cohort study

Objectives
To present data on the prevalence and severity of GI bleeding in critically ill patients in the ICU, and to describe current practice of SUP

Study Design
A multicentre 7-day inception cohort study

Outcomes
Mortality and GI bleeding

Study Duration
7 days

Number of subjects
1,000

Population
Adult critically ill patients in the ICU

GLOSSARY OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>ABBREVIATION</th>
<th>TERM</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRF</td>
<td>Case report form</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>H2RA</td>
<td>Histamine 2 receptor antagonist</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>OR</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>PPI</td>
<td>Proton pump inhibitor</td>
</tr>
<tr>
<td>PI</td>
<td>Principal investigator</td>
</tr>
<tr>
<td>SUP</td>
<td>Stress ulcer prophylaxis</td>
</tr>
</tbody>
</table>
1. INVESTIGATORS AND FACILITIES

1.1 Study Locations

**Denmark**
Department of Intensive Care 4131
Copenhagen University Hospital Rigshospitalet

Department of Intensive Care Medicine
Copenhagen University Hospital Bispebjerg

Department of Intensive Care Medicine
Odense University Hospital

More to be added.

**United Kingdom**
Department of Adult Critical Care
University Hospital of Wales

More to be added

**Sweden**
To be announced.

**Norway**
To be announced.

**Iceland**
To be announced.

**Finland**
Department of Intensive Care Medicine
Kuopio University Hospital

More to be added

**The Netherlands**
Department of Critical Care
University Medical Centre Groningen

**Italy**
San Martino Hospital, Genoa

**Canada**
McMaster University
New Zealand
Department of Critical Care Medicine
Auckland City Hospital

More to be added.

Australia
To be announced

1.2 Study Management
The Steering and Management Committee will manage and coordinate the study centrally. A locale research team consisting of a Principal Investigator and a study coordinator will manage and coordinate the study locally. The Principal Investigator has the responsibility for data collection and maintenance of study documentation (Appendix 1).

1.2.1 Principal Investigators
Denmark
Mette Krag, MD
Dept. of Intensive Care 4131
Copenhagen University Hospital Rigshospitalet

More to be added

United Kingdom
Matthew Wise, MD PhD
Dept. of Adult Critical Care
University Hospital of Wales

Mark Borthwick, B.Pharm, MSc
Dept. of Pharmacy
John Radcliffe Hospital
Oxford University Hospitals NHS Trust

More to be added.

Sweden
To be announced.

Norway
To be announced.

Iceland
To be announced.

Finland
Stepani Bendel, MD PhD
Dept. of Intensive Care Medicine
Kuopio University Hospital

The Netherlands
Eric Keus, MD PhD
Department of Critical Care
University Medical Centre Groningen
The Netherlands

Italy
Paolo Pelosi
San Martino Hospital, Genoa

Canada
Deborah Cook, Professor

Australia/ New Zealand
Colin McArthur, MD, Clinical Director
Department of Critical Care Medicine
Auckland City Hospital

1.2.2 Statistician
To be announced.

1.2.3 Steering and Management Committee
Mette Krag, MD
Dept. of Intensive Care 4131
Copenhagen University Hospital Rigshospitalet

Morten Hylander Møller, MD PhD
Dept. of Intensive Care 4131
Copenhagen University Hospital Rigshospitalet

Anders Perner, MD PhD
Dept. of Intensive Care 4131
Copenhagen University Hospital Rigshospitalet

Jørn Wetterslev, MD PhD
Copenhagen Trial Unit
Copenhagen University Hospital Rigshospitalet

Matthew Wise, MD PhD
Dept. of Adult Critical Care
University Hospital of Wales

Colin McArthur, MD, Clinical Director
Dept. of Critical Care Medicine
Auckland City Hospital
SUP-ICU Protocol

Stepani Bendel, MD PhD
Dept. of Intensive Care Medicine
Kuopio University Hospital

1.3 Sponsors
Morten Hylander Møller, MD PhD; Anders Perner, MD PhD
Dept. of Intensive Care 4131
Copenhagen University Hospital Rigshospitalet

1.4 Funding and resources
The Scandinavian Society of Anaesthesia and Intensive Care Medicine
Aase and Ejnar Danielsens Foundation

The study is not industrial sponsored.

2. INTRODUCTION AND BACKGROUND

2.1 Background Information
Critically ill patients are at risk of stress-related gastrointestinal (GI) bleeding. The reported incidences of GI bleeding in the ICU ranges from 2-15%, however, data derives from research published 15-20 years ago. As a result of substantial changes in intensive care practice over the last 10-20 years, the incidence of stress ulceration in critically ill patients may have changed.

The two major risk factors for stress-related GI bleeding are mechanical ventilation ≥ 48 hours (odds ratio (OR) 15.6) and coagulopathy (OR 4.3). GI bleeding due to stress ulceration is associated with increased mortality.

Older trials have suggested that SUP can reduce the frequency of GI bleeding in ICU patients compared to placebo or no prophylaxis, and SUP is regarded as a standard of care in ICU as outlined by the Surviving Sepsis Campaign guidelines.

However, recent research has questioned the rationale and level of evidence of SUP in ICU patients, because of limited data, methodological flaws in some of the trials, a possible increased incidence of nosocomial pneumonia and clostridium difficile enteritis following use of SUP, and general improvements in intensive care.

2.2 Research Question
Specific research questions
“What is the prevalence of GI bleeding in general ICUs in 2013?”
“What is the current practice of SUP in general ICUs in 2013?”

Overall research question of the SUP-ICU research programme
“Is SUP indicated for critically ill patients in the ICU?”

2.3 Rationale for Current Study
The reported incidence of GI bleeding in the literature is 15-20 years old and varies considerably for several reasons. Firstly no consensus definition of GI bleeding has been used. Secondly GI bleeding data have been derived from different ICU subpopulations. In addition, intensive care practice has markedly changed over the last 20 years, so old data may not inform us about the current incidence. The present use of SUP in the ICU needs to be described, including the preferred SUP agents used. It is unknown which SUP agent has the optimal balance between benefit and harm, and if SUP in the ICU is indicated at all. This is due to high risk of
bias, increased risk of random error as the required information size for a reasonable intervention effect has not yet been reached, and possible design errors and insufficient data on the effect on mortality. Consequently, updated data on current SUP practice in the ICU, and on the incidence and severity of GI bleeding is warranted.

3. STUDY OBJECTIVES
3.1 Primary Objective
To describe the prevalence and severity of GI bleeding in critically ill patients in the ICU, and to describe current practice of SUP.

4. STUDY DESIGN
4.1 Type of study
A multicentre 7-day inception cohort study investigating the prevalence of GI bleeding and current use of SUP in critically ill patients in the ICU.

4.2 Study design diagram
See Appendix 2 in page 16.

4.3 Number of subjects
A total of 1,000 critically ill patients in general ICUs are expected to be included.

4.4 Expected duration of study
Seven days with 90 days follow-up.

4.5 Primary and secondary outcome measures
Primary
Clinical significant GI bleeding
(Definition: overt GI bleeding AND ≥1 of the following features within 24 hours of GI bleeding: 1) spontaneous drop of systolic, mean arterial pressure or diastolic blood pressure of 20 mmHg or more, 2) start of vasopressor or a 20% increase in vasopressor dose 3) decrease in hemoglobin of at least 2 g/dl (1.24 mmol/L), or 4) transfusion of 2 units of packed red blood cells or more)

Secondary
Overt GI bleeding
(Definition: hematemesis, coffee ground emesis, melena, hematochezia or bloody nasogastric aspirate)

90-day mortality
(Definition: death within 90-days of the index date)

Crude and adjusted relative risks for GI bleeding and 90-day mortality

5. RECRUITMENT
5.1 Recruitment
Potential subjects will be identified and recruited in the ICU by the locale Principal Investigator.

5.2 Eligibility criteria

5.2.1 Inclusion Criteria
All adult (age ≥18 years) critically ill patients admitted acutely to one of the study ICUs during the 7-day study period.

5.2.2 Exclusion Criteria
Age <18 years
Observed upper GI-bleeding and/or treatment for upper GI-bleeding during current hospital admission
Planned ICU admission (e.g. after elective surgery)
Previously ICU admission during current hospital admission before the 7-day study period

5.3 Readmission to an ICU
When patients included in the 7-day study period are discharged from the ICU and, during same hospital admission, are readmitted to an ICU participating in SUP-ICU, the day form registration will be continued.

Patients admitted to an ICU during current hospital admission before the 7-day study period will be excluded during screening procedure

5.4 Patients transferred between hospitals
Patients transferred from an ICU participating in SUP-ICU to another ICU participating in SUP-ICU: day form registration will be continued at the receiving hospital and the investigator at the last hospital will complete follow-up

Patients transferred from an ICU participating in SUP-ICU to an ICU not participating in SUP-ICU: day form data will no longer be collected, but follow-up data will be registered at day 90

Patients transferred from an ICU not participating in SUP-ICU to an ICU participating in SUP-ICU: the patient cannot be included in the study

5.5 Study closure
When the 7-day study period and the 90-day follow-up period has ended.

6. CLINICAL AND LABORATORY ASSESSMENTS - METHODOLOGY
An overview is presented in Figure 2, page 16.

6.1 Patient evaluation

Baseline patient characteristics
1. Age on day of ICU admission (years)
2. Gender (male/female)
3. SAPS 2 on day of ICU admission (0-163 points)
4. SOFA score on day of ICU admission (0-24 points)
5. Days admitted in hospital (days)
6. Treatment with ulcer prophylactic drugs (PPI, H2RA, antacids or sucralfate) prior to hospital/ICU admission
7. Treatment with NSAID/acetylsalicylic acid or anticoagulant drugs prior to hospital/ICU admission
8. Comorbid conditions (choose one or more)
   a. History of COPD
   b. History of heart failure or myocardial infarction
   c. History of chronic renal failure (need for chronic renal support or S-creatinine > 3.6 g/dL / 300 μmol/L prior to hospital admission)
   d. History of liver cirrhosis or increased bilirubin
   e. Immunosuppression (at least 0.3 mg/kg per day of a prednisolone equivalent for at least 1 month in the 6 months prior to ICU admission)
   f. Surgical intervention (elective or emergency) prior to ICU admission?
   g. Treatment with prednisolone? (at least 0.3 mg/kg/day of prednisolone equivalent for at least 1 month in the 6 months prior to ICU admission)
   h. Coagulopathy during current hospital admission or at ICU admission? (Platelet count < 50 and/or international normalized ratio (INR) > 1.5)

**Daily from ICU admission to end of the 90th day of follow-up or discharge from ICU**
9. Treatment with continuous vasopressor (Noradrenaline, adrenaline, dobutamine, dopamine, vasopressin, levosimendan or milniron)
10. Treatment with continuous/intermittent renal replacement therapy
11. Intubation and mechanical ventilation (invasive)
12. Lowest platelet count the last 24 hours? (if registered)
13. Highest International Normal Ratio (INR) the last 24 hours? (if registered)
14. Treatment with NSAID and acetylsalicylic acid
15. Treatment with anticoagulant drugs
16. Treatment with intravenous thrombolysis
17. Treatment with ulcer prophylactic drugs (PPI, H2RA, sucralfate, antacids, prostanoids)
18. Volume of tube feeding on this day?
19. Post pyloric/jejunal feeding?
20. Any oral intake?
21. Upper GI-bleeding (hematemesis, coffee ground mesis, melena, hematochezia or bloody nasogastric aspirate or positive aspirate blood test without overt bleedig)
22. Clinical significant bleeding (see definition in section 4.5)
23. Endoscopic finding (ulcer, gastritis, esophageal varices)
24. Treatment of bleeding
25. Lowest haemoglobin on the day the patient had upper GI-bleeding
26. Units of red blood cells given on the day the patient had upper GI-bleeding

**Day 90 after the study index date**
27. Vital status (dead/alive)?
28. Discharged from ICU? (y/n)
29. Length of hospital/ICU admission

6.2 **Unit/department evaluation**
30. Type of Hospital (University/Teaching/District/General/Specialist)?
31. Type of ICU (Medical/Surgical/Mixed)?
32. Number of ICU beds open for admission (e.g. 20)?
33. Does your ICU have a general guideline/protocol for use of SUP? (y/n)
34. Does your ICU have a guideline/protocol for use of SUP in specific subgroup of patients? (y/n)
35. When do you stop SUP? (full enteral feed/discontinuation of mechanical ventilation/ICU discharge/other)
36. Do you consider SUP treatment safe? (y/n)
37. Which (if any) of the following potential adverse effects are you worried about? (Nosocomial Pneumonia/Clostridium difficile enteritis/Abscess formation/Rash/Interstitial Nephritis/Delirium/Cardiac Arrhythmias/Myocardial infarction/Drug Interactions/Death/Other/None)

7. STATISTICAL METHODS

7.1 Sample size estimation
In a cross sectional study with simple random sampling, α=0.05, β=0.2, and an estimated incidence of GI bleeding in the ICU of 2-4%, inclusion of at least 1,000 patients are required to yield a confidence interval of an incidence rate of 2% ranging from 1.1% to 2.9% or for 4% ranging from 2.8% to 5.2%. An estimated 75 ICUs will be needed.

7.2 Population to be analysed
All patients who are acutely admitted to one of the study ICUs at any point of the 7-day study period (Monday 00:01 to Sunday 23:59).

7.3 Statistical analysis plan
Continuous variables will be evaluated for significant deviations from the normality assumption using the Kolmogorov-Smirnov test and histograms. Non-parametric tests of comparison will be used for variables evaluated as not normally distributed. Difference testing between groups will be performed using analysis of variance, Kruskal-Wallis test, Cochran-Armitage trend test, t test, Mann-Whitney test, Chi²-test, and Fishers exact test, as appropriate. For multiple comparisons Bonferroni corrected P.values will be presented and evaluated as well. Multivariate logistic regression analysis will be used to determine crude and adjusted risk for GI bleeding and 90-day mortality. Data will be presented as mean (95% confidence interval), median (interquartile range [IQR]), or number (%) as appropriate. All statistical tests will be 2-tailed, and P<.05 is considered statistically significant.

Prior to conducting analysis, a detailed statistical plan will be prepared and made available online (www.sup-icu.com).

8. DATA HANDLING

8.1 Records to be kept / Data Collection
Data will continuously be collected on case report forms (CRFs) from source data (patient records, laboratory reports and surveys) the day the study is conducted. Subsequently, the data on the CRFs is entered into an electronic database.

8.2 Data Management / Quality control
The locale Principal Investigators will check the completed CRFs for completeness and accuracy against the source data. Original CRFs will be used when entering information into the electronic database. The database will be checked against the CRFs for accuracy. No investigation of the data will begin until an accurate database has been assured.

8.3 Study Record Retention
All research data and study related documents will be stored confidentially and securely for 15 years in the Department of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet following the end of the study. The members of the Steering and Management Committee have access to the stored data. Upon request, investigators will get data from their own unit.

9. ADMINISTRATIVE ASPECTS

9.1 Confidentiality
Subject confidentiality is strictly held in trust by the participating investigators, research staff, and the sponsoring institution. The study protocol, documentation, data and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party, without prior written approval of the sponsoring institution. Authorized representatives of the sponsoring institution may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic or hospital) and pharmacy records for the subjects in this study. The clinical study site will permit access to such records. All laboratory specimens, evaluation forms, reports and other records that leave the site will be identified only by the Subject Identification Number (SIA) to maintain subject confidentiality.

9.2 Approvals
This protocol and any subsequent modifications will be reviewed and approved by the National Data Protection Agencies. A letter of protocol approval by the National Data Protection Agency will be obtained prior to the commencement of the study.

9.3 Modifications of the protocol
The study will be conducted in compliance with the current version of the protocol. Any change to the protocol document that affects the scientific intent, study design, or results is considered an amendment, and therefore will be written and filed as an amendment to the protocol.

9.4 Financial Disclosure and obligations
All participating researchers are obliged to declare any conflicts of interest or financial interest related to the study.

10. USE OF DATA AND PUBLICATIONS POLICY
The study will be reported to the National Data Protection Agencies and Ethics Committee, as appropriate. The final protocol will be available upon request. Upon study completion the main manuscript will be submitted to one of the major clinical
journals regardless of the result, and the results will in any case be published at the SUP-ICU home page (www.sup-icu.com). The listing of authors will be as follows: M Krag will be the first author. M Wise / A Perner / M Borthwick / J Wetterslev will be the second, third, fourth and fifth author. MH Møller will be the last and corresponding author, and then ‘the SUP-ICU research group and Scandinavian Critical Care Trials Group’ will be written. If new members of the Steering and Management Committee are appointed these will also become co-authors if they fulfil the Vancouver definitions. If other trial groups participate these will appear after the SCCTG. The members of the SUP-ICU research group and other persons who contribute considerably will be investigators; these will appear in an appendix to the main paper.

The Steering and Management Committee will grant more personal authorships depending on personal input according to the Vancouver definitions. Funding sources will have no influence on data handling or analyses or writing of the manuscript.
Publication of data from a single-centre needs to be approved by the Steering and Management Committee. An investigator, a group of investigators or a trial group involved in SUP-ICU can get access to the full dataset to analyze a specific research question. In that case, a written protocol has to be submitted and approved by the Steering and Management Committee.
The Steering and Management Committee holds the primary responsibility for publication of the results of the study.
11. REFERENCES


12. APPENDIX 1:

RESEARCH PROGRAMME ORGANISATION

Steering and Management Committee
- Matti Kräg, Coordinating Investigator
  Dept. of Intensive Care 431, Rigshospitalet (Denmark)
- Morten Hylander Müller, Initiator
  Dept. of Intensive Care 431, Rigshospitalet (Denmark)
- Andra Pernar, Initiator
  Dept. of Intensive Care 431, Rigshospitalet (Denmark)
- Jern Wetterlev, Tidlak
  Copenhagen Trial Unit (Denmark)
- Matt P Wise, National Investigator
  Dept. of Amul Critical Care, University Hospital of Wales (United Kingdom)
- Colin McArthur, National Investigator
  Dept. of Critical Care Medicine, Auckland City Hospital (New Zealand)
- Stefanie Bueckel, National Investigator
  Dept. of Intensive Care Medicine, Kuopio University Hospital (Finland)
- Scandinavian Critical Care Trial Group (SCTG)
- Good Clinical Practice
- Data Protection Agency
- National Committee on Biomedical Research Ethics

Monitoring and Safety Committee
Scientific Committee

Copenhagen Trial Unit
Jern Wetterlev, Tidlak
Copenhagen Trial Unit (Denmark)

Denmark
National Investigator: Matti Kräg

Iceland
National Investigator: Alma Mattar

Finland
National Investigator: Stefanie Bueckel

UK
National Investigator: Matthew Wise

Italia
National Investigator: Paolo Pichli

Australia
National Investigator: Colin McArthur

New Zealand
National Investigator: Colin McArthur

Canada
National Investigator: Deborah Cook

Norway
National Investigator: Arne Bert Selvik

The Netherlands
National Investigator: Eric Keus

Sweden
National Investigator: Micke Jansen
13. APPENDIX 2

STUDY DESIGN DIAGRAM

Day 0  Daily until ICU discharge (max. 90 days)  Day 90

ICU admission  Follow-up

Age  Gender  Comorbidity  SOFA score  SAPS 2  Type of admission  Hospital admission date  INR/CRRT?  Coagulopathy?  Mechanical ventilation?  SUP data  Nutrition data  GI bleeding data  Vasoressors?  Vital status  Discharged from ICU

All patients admitted to the ICU between
Monday dd/mm/yyyy 06.00 am
and
Monday dd/mm/yyyy 05.59 am
(7 days)

Follow-up with daily registration until discharge from ICU or death

SUP-ICU study diagram